

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202411085192 A

(19) INDIA

(22) Date of filing of Application :06/11/2024

(43) Publication Date : 22/11/2024

(54) Title of the invention : PHARMACOLOGICAL INTERVENTION FOR LIVER REGENERATION THROUGH GSK-3 $\beta$  INHIBITION AND RELATED METHODS

(51) International classification	:A61K9/20, A61K9/14, A61K47/38, A61K47/32, A61K47/36, A61K47/02, A61K47/12, A61K31/506	(71)Name of Applicant : <b>1)Chitkara University</b> Address of Applicant :Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India -----
(86) International Application No	:NA	<b>2)Chitkara Innovation Incubator Foundation</b> Name of Applicant : NA
Filing Date	:NA	Address of Applicant : NA
(87) International Publication No	: NA	(72)Name of Inventor : <b>1)Onkar Bedi</b> Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -----
(61) Patent of Addition to Application Number	:NA	<b>2)Thakur Gurjeet Singh</b> Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -----
Filing Date	:NA	<b>3)Manisha Choudhary</b> Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -----
(62) Divisional to Application Number	:NA	
Filing Date	:NA	

(57) Abstract :

ABSTRACT The invention relates to a composition for promoting liver regeneration and providing a hepatoprotective effect. It comprises a selective GSK-3 $\beta$  inhibitor, which is a chemical compound that inhibits GSK-3 $\beta$  activity, and a pharmaceutically acceptable carrier. The selective GSK-3 $\beta$  inhibitor accumulates  $\beta$ -catenin and activates the Wnt/ $\beta$ -catenin signaling pathway in the liver, thereby stimulating liver regeneration and repair. The composition can be formulated for oral, intravenous, or intraperitoneal administration. Additionally, a solid oral composition is described, which includes the selective GSK-3 $\beta$  inhibitor and one or more pharmaceutically acceptable excipients, formulated as a tablet with specific amounts of diluents, binders, disintegrants, and lubricants. A method for promoting liver regeneration and providing a hepatoprotective effect by administering the composition to a subject with liver toxicity or damage is also disclosed. Reference Fig 1

No. of Pages : 30 No. of Claims : 10